Abstract: Objective: To investigate the clinical effect and adverse reaction of AC (pirarubicin/cyclophosphamide) and PA (paclitaxel/pirarubicin) adjuvant chemotherapeutic regimens for patients with resectable breast cancer and analyze the influencing factors of prognosis. Methods:The disease-free survival (DFS), overall survival (OS) and adverse effect in 102 of the 294 patients with adjuvant chemotherapeutic AC regimen and the other 192 with PA regimen for breast cancer during a period from December2003 to December 2005 were discussed, and a stepwise analysis of possible prognostic factors was conducted. Results: DFS rate of the patients administered with the AC and PA regimens achieved93.1% and 73.4% re-spectively, and the OS rate was 98.0% and 90.1% in turn in the two groups. There were statistically significant differences in the relapse and OS rates between the patients with T 1 and T 2 (or above), those with 0-3 LN positive and4 LN positive plus, and those with stage I+II and stage III breast cancers ( P=0.005 , P<0.001 , P<0.001 ). There were also significant differ -ences in the relapse rates between the patients with hormone receptor-positive and -negative disease (P =0.045 ). Cox analysis showed the number of positive lymph nodes, clinico-pathologic staging and hormone receptor status were the in-dependent prognostic indicators. Adverse effect of grade III and above, bone marrow depression, alopecia, gastrointestinal reaction and cardiac accident were respectively 10%,2%,11% and 0% in the cases with AC regimen, and33%,90%,13% and 1% in cases with PA regimen. Conclusion:The curative effects of the AC regimen with 4 to 6 courses and PA regimen with 6 courses are positive to the patients with operable breast cancer, and the drug toxicity is acceptable. Thus, these regi -mens are the recommended methods of adjuvant chemotherapy for breast cancer. The LN status, TNM staging and hor-mone receptor status are the independent prognostic indicators.